Dual targeting of the class V lanthipeptide antibiotic cacaoidin
Julia P. Deisinger,
Melina Arts,
Ioli Kotsogianni,
Jan-Samuel Puls,
Fabian Grein,
Francisco Javier Ortiz-López,
Nathaniel I. Martin,
Anna Müller,
Olga Genilloud,
Tanja Schneider
Affiliations
Julia P. Deisinger
Institute for Pharmaceutical Microbiology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany; DZIF, German Center for Infectious Research, Partner Site Bonn-Cologne, Bonn, Germany
Melina Arts
Institute for Pharmaceutical Microbiology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany
Ioli Kotsogianni
Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2333 Leiden, the Netherlands
Jan-Samuel Puls
Institute for Pharmaceutical Microbiology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany
Fabian Grein
Institute for Pharmaceutical Microbiology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany; DZIF, German Center for Infectious Research, Partner Site Bonn-Cologne, Bonn, Germany
Francisco Javier Ortiz-López
Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avenida del Conocimiento, 34. Parque Tecnológico de Ciencias de la Salud, Armilla, 18016 Granada, Spain
Nathaniel I. Martin
Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2333 Leiden, the Netherlands
Anna Müller
Institute for Pharmaceutical Microbiology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany
Olga Genilloud
Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avenida del Conocimiento, 34. Parque Tecnológico de Ciencias de la Salud, Armilla, 18016 Granada, Spain
Tanja Schneider
Institute for Pharmaceutical Microbiology, University of Bonn, Meckenheimer Allee 168, 53115 Bonn, Germany; DZIF, German Center for Infectious Research, Partner Site Bonn-Cologne, Bonn, Germany; Corresponding author
Summary: Antibiotic resistance is reaching alarming levels, demanding for the discovery and development of antibiotics with novel chemistry and mechanisms of action. The recently discovered antibiotic cacaoidin combines the characteristic lanthionine residue of lanthipeptides and the linaridin-specific N-terminal dimethylation in an unprecedented N-dimethyl lanthionine ring, being therefore designated as the first class V lanthipeptide (lanthidin). Further notable features include the high D-amino acid content and a unique disaccharide substitution attached to the tyrosine residue. Cacaoidin shows antimicrobial activity against gram-positive pathogens and was shown to interfere with peptidoglycan biosynthesis. Initial investigations indicated an interaction with the peptidoglycan precursor lipid IIPGN as described for several lanthipeptides. Using a combination of biochemical and molecular interaction studies we provide evidence that cacaoidin is the first natural product demonstrated to exhibit a dual mode of action combining binding to lipid IIPGN and direct inhibition of cell wall transglycosylases.